- Home
- KROS vs CTNM Comparison
KROS vs CTNM Comparison
Compare KROS & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KROS | CTNM |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 575.3M |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | KROS | CTNM |
|---|---|---|
| Price | $16.57 | $14.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $23.00 | $18.60 |
| AVG Volume (30 Days) | ★ 266.1K | 251.6K |
| Earning Date | 03-03-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $246,718,000.00 | N/A |
| Revenue This Year | $6,924.79 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.53 | ★ N/A |
| Revenue Growth | ★ 37798.31 | N/A |
| 52 Week Low | $9.12 | $3.35 |
| 52 Week High | $22.55 | $16.01 |
Technical Indicators
Market Signals| Indicator | KROS | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 62.68 |
| Support Level | $16.31 | $14.59 |
| Resistance Level | $17.17 | $16.01 |
| Average True Range (ATR) | 0.63 | 1.09 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 18.26 | 68.40 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.